[SCHEDULE 13G/A] Corvus Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. Schedule 13G/A (Amendment No. 5) was filed by Samlyn Capital, LLC, Samlyn, LP and Robert Pohly reporting zero beneficial ownership of Corvus common stock (CUSIP 221015100) as of the event date 06/30/2025. The filing identifies the reporting persons, their Delaware or U.S. organization, principal office addresses, and confirms 0 shares, 0% ownership with no sole or shared voting or dispositive power. The filing includes Exhibit A (Joint Filing Agreement) and Exhibit B (Control Person Identification) and is signed by Robert Pohly on 08/14/2025.

Positive

• Clear disclosure of reporting persons and principal business addresses, aiding regulatory transparency
• Affirms zero beneficial ownership (0 shares; 0%), eliminating claims of influence or control as of 06/30/2025

Negative

• None.

Insights

Securities Analyst

TL;DR: A formal disclosure showing the Samlyn filers hold no beneficial position in CRVS, so no investor influence is claimed.

The Schedule 13G/A reports 0 shares (0%) beneficially owned by Samlyn Capital, Samlyn, LP and Robert Pohly as of 06/30/2025. The filing is procedural and confirms transparency under beneficial ownership rules; it does not disclose any holdings, voting power, or dispositive power. For market impact, the statement itself is neutral because no economic stake or control intent is reported.

Corporate Governance Expert

TL;DR: The amendment documents compliance and identifies control-party exhibits, but shows no ownership or governance influence.

The filing includes Exhibit A and Exhibit B and is signed by Robert Pohly, indicating proper execution of filing formalities. With 0 shares and 0% ownership, the report signals no current governance influence by the reporting persons. The document serves compliance and disclosure purposes rather than signaling a governance change or activism.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

Corvus Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

221015100

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 221015100

1

Names of Reporting Persons

SAMLYN CAPITAL, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 221015100

1

Names of Reporting Persons

SAMLYN, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 221015100

1

Names of Reporting Persons

ROBERT POHLY

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Corvus Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080, United States of America
Item 2.
(a)	Name of person filing: Samlyn Capital, LLC Samlyn, LP Robert Pohly
(b)	Address or principal business office or, if none, residence: Samlyn Capital, LLC 500 Park Avenue, 2nd Floor New York, New York 10022 United States of America Samlyn, LP c/o Samlyn Capital, LLC 500 Park Avenue, 2nd Floor New York, New York 10022 United States of America Robert Pohly c/o Samlyn Capital, LLC 500 Park Avenue, 2nd Floor New York, New York 10022 United States of America
(c)	Citizenship: Samlyn Capital, LLC - Delaware Samlyn, LP - Delaware Robert Pohly - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 221015100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0
(b)	Percent of class: Samlyn Capital, LLC - 0% Samlyn, LP - 0% Robert Pohly - 0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0
	(ii) Shared power to vote or to direct the vote: Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0
	(iii) Sole power to dispose or to direct the disposition of: Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0
	(iv) Shared power to dispose or to direct the disposition of: Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Please see Exhibit B attached hereto
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SAMLYN CAPITAL, LLC

Signature:	By: Samlyn, LP, its sole member, By: Samlyn GP, LLC, its general partner, By: /s/ Robert Pohly
Name/Title:	Robert Pohly, Managing Member
Date:	08/14/2025

SAMLYN, LP

Signature:	By: Samlyn GP, LLC, its general partner, By: /s/ Robert Pohly
Name/Title:	Robert Pohly, Managing Member
Date:	08/14/2025

ROBERT POHLY

Signature:	By: /s/ Robert Pohly
Name/Title:	Robert Pohly
Date:	08/14/2025

Exhibit Information

Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification

FAQ

Who filed the Schedule 13G/A for Corvus Pharmaceuticals (CRVS)?

The filing was made by Samlyn Capital, LLC, Samlyn, LP and Robert Pohly.

How many Corvus (CRVS) shares do the filers beneficially own?

The filers report 0 shares, representing 0% of the class.

What is the event date reported on this Schedule 13G/A?

The date of the event requiring the filing is 06/30/2025.

When was the Schedule 13G/A signed?

Signatures on the filing are dated 08/14/2025, signed by Robert Pohly.

Does the filing include any exhibits?

Yes; the filing references Exhibit A (Joint Filing Agreement) and Exhibit B (Control Person Identification).